Tenet Healthcare Raises 2026 Guidance, Stock Looks Cheap at 13.9x

NEW YORK, November 8 —

Tenet Healthcare Corporation (THC) raised its 2026 guidance, challenging the market's bet on a steep earnings decline from the $34.29 trailing EPS already on the books.

The Trailing Multiple Hiding Behind That Forward Figure

At $283.33 with $34.29 in trailing EPS, THC trades at roughly 8x on a trailing basis. The forward multiple is higher because consensus has already priced in a meaningful earnings decline for the year ahead. That embedded pessimism is exactly what the guidance raise is pushing against. If management's revised 2026 numbers hold closer to trailing levels, the re-rating is a matter of arithmetic, not narrative.

$2 Billion in Cash From $22.2 Billion in Revenue

Generating $2bn in FCF on $22.2bn in revenue, roughly a 9% cash margin, is not a given for a capital-intensive hospital operator contending with labor inflation, payer renegotiations, and facility costs at scale. Tenet has done it on a revenue base growing 6.5% YoY. That combination of expansion and cash conversion gives management a credible platform to raise guidance rather than merely defend the existing range. It also funds the capital allocation decisions that shift multiples over time.

A Guidance Raise Is Not a Beat

A quarterly earnings beat is backward-looking by definition. A full-year guidance raise is a commitment about what comes next. Hospital operators carry enough visibility into their contract cycles, admissions volumes, and payer mix to know when raising guidance is a defensible call versus a rounding-error adjustment. Raising 2026 targets now puts a stake in the ground. Consensus models will reset higher, compressing the forward multiple before the stock moves a dollar; that is what multiple expansion looks like before it shows up on a chart.

The 2026 Adjusted EBITDA Range That Settles the Argument

Specific figures matter here. A modest uplift keeps THC's setup roughly unchanged. A substantive revision toward trailing earnings levels forces a full consensus reset and a re-rating that the current multiple cannot absorb quietly. Watch both the midpoint and the width: a narrow guidance band signals management conviction; a wide range signals caution dressed as optimism. At that multiple on current estimates, the entry multiple for a renewed bull case is not demanding. The number to watch is updated 2026 adjusted EBITDA, to be disclosed in Tenet's next 8-K or investor presentation.

For a comprehensive view of Tenet Healthcare's valuation, margins, and earnings history, generate a full analysis at Basis Report's THC stock page. To pressure-test the thesis against different growth and discount assumptions, run the numbers in the DCF calculator.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.